Ensoma Focuses on Key Gene Therapy, Cuts Staff
Ensoma reduced its staff and paused some programs to focus on its main gene therapy for a rare immune disease.
Biotech company Ensoma changed its plans. The company now focuses on its top gene therapy. This therapy treats a rare immune disease.
Ensoma let go of some employees. This follows earlier staff reductions last November. The company also stopped some early-stage research. These moves help Ensoma save money. They also put more effort into the most promising treatment.
The company believes in its lead gene therapy. This treatment could help people with a serious health problem. By focusing, Ensoma hopes to bring this medicine to patients faster.
This decision shows how biotech companies adapt. They make tough choices to develop new medicines. Their goal is to find cures for complex diseases.
Source: FierceBiotech
More from Biotech
